|
1
|
Wei WI and Sham JS: Nasopharyngeal
carcinoma. Lancet. 365:2041–2054. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Feng XP, Yi H, Li MY, Li XH, Yi B, Zhang
PF, Li C, Peng F, Tang CE, Li JL, et al: Identification of
biomarkers for predicting nasopharyngeal carcinoma response to
radiotherapy by proteomics. Cancer Res. 70:3450–3462. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Leung SF, Teo PM, Shiu WW, Tsao SY and
Leung TW: Clinical features and management of distant metastases of
nasopharyngeal carcinoma. J Otolaryngol. 20:27–29. 1991.PubMed/NCBI
|
|
4
|
Lee AW, Poon YF, Foo W, Law SC, Cheung FK,
Chan DK, Tung SY, Thaw M and Ho JH: Retrospective analysis of 5037
patients with nasopharyngeal carcinoma treated during 1976–1985:
Overall survival and patterns of failure. Int J Radiat Oncol Biol
Phys. 23:261–270. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chan JY, Chow VL, Tsang R and Wei WI:
Nasopharyngectomy for locally advanced recurrent nasopharyngeal
carcinoma: Exploring the limits. Head Neck. 34:923–928. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee AW, Ng WT, Chan YH, Sze H, Chan C and
Lam TH: The battle against nasopharyngeal cancer. Radiother Oncol.
104:272–278. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Garzon R, Calin GA and Croce CM: MicroRNAs
in cancer. Annu Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shenouda SK and Alahari SK: MicroRNA
function in cancer: Oncogene or a tumor suppressor? Cancer
Metastasis Rev. 28:369–378. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu X, Lv XB, Wang XP, Sang Y, Xu S, Hu K,
Wu M, Liang Y, Liu P, Tang J, et al: MiR-138 suppressed
nasopharyngeal carcinoma growth and tumorigenesis by targeting the
CCND1 oncogene. Cell Cycle. 11:2495–2506. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pause A, Belsham GJ, Gingras AC, Donzé O,
Lin TA, Lawrence JC Jr and Sonenberg N: Insulin-dependent
stimulation of protein synthesis by phosphorylation of a regulator
of 5′-cap function. Nature. 371:762–767. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Meric F and Hunt KK: Translation
initiation in cancer: A novel target for therapy. Mol Cancer Ther.
1:971–979. 2002.PubMed/NCBI
|
|
12
|
Yu L, Shang ZF, Wang J, Wang H, Huang F,
Zhang Z, Wang Y, Zhou J and Li S: PC-1/PrLZ confers resistance to
rapamycin in prostate cancer cells through increased 4E-BP1
stability. Oncotarget. 6:20356–20369. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Glaser R, Zhang HY, Yao KT, Zhu HC, Wang
FX, Li GY, Wen DS and Li YP: Two epithelial tumor cell lines (HNE-1
and HONE-1) latently infected with Epstein-Barr virus that were
derived from nasopharyngeal carcinomas. Proc Natl Acad Sci USA.
86:9524–9528. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang DP, Ho JH, Poon YF, Chew EC, Saw D,
Lui M, Li CL, Mak LS, Lai SH and Lau WH: Establishment of a cell
line (NPC/HK1) from a differentiated squamous carcinoma of the
nasopharynx. Int J Cancer. 26:127–132. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kuo LJ and Yang LX: Gamma-H2AX - a novel
biomarker for DNA double-strand breaks. In Vivo. 22:305–309.
2008.PubMed/NCBI
|
|
16
|
Paglin S, Hollister T, Delohery T, Hackett
N, McMahill M, Sphicas E, Domingo D and Yahalom J: A novel response
of cancer cells to radiation involves autophagy and formation of
acidic vesicles. Cancer Res. 61:439–444. 2001.PubMed/NCBI
|
|
17
|
Tilton SC, Tal TL, Scroggins SM, Franzosa
JA, Peterson ES, Tanguay RL and Waters KM: Bioinformatics Resource
Manager v2.3: An integrated software environment for systems
biology with microRNA and cross-species analysis tools. BMC
Bioinformatics. 13:3112012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rhodes DR, Yu J, Shanker K, Deshpande N,
Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM:
ONCOMINE: A cancer microarray database and integrated data-mining
platform. Neoplasia. 6:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang W, Zhao LJ, Tan YX, Ren H and Qi ZT:
MiR-138 induces cell cycle arrest by targeting cyclin D3 in
hepatocellular carcinoma. Carcinogenesis. 33:1113–1120. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang H, Luo J, Liu Z, Zhou R and Luo H:
MicroRNA-138 regulates DNA damage response in small cell lung
cancer cells by directly targeting H2AX. Cancer Invest. 33:126–136.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sossey-Alaoui K and Plow EF:
miR-138-mediated regulation of KINDLIN-2 expression modulates
sensitivity to chemotherapeutics. Mol Cancer Res. 14:228–238. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang H, Tang Y, Guo W, Du Y, Wang Y, Li P,
Zang W, Yin X, Wang H, Chu H, et al: Up-regulation of microRNA-138
induce radiosensitization in lung cancer cells. Tumour Biol.
35:6557–6565. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Larsson O, Li S, Issaenko OA, Avdulov S,
Peterson M, Smith K, Bitterman PB and Polunovsky VA: Eukaryotic
translation initiation factor 4E induced progression of primary
human mammary epithelial cells along the cancer pathway is
associated with targeted translational deregulation of oncogenic
drivers and inhibitors. Cancer Res. 67:6814–6824. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Avdulov S, Li S, Michalek V, Burrichter D,
Peterson M, Perlman DM, Manivel JC, Sonenberg N, Yee D, Bitterman
PB, et al: Activation of translation complex eIF4F is essential for
the genesis and maintenance of the malignant phenotype in human
mammary epithelial cells. Cancer Cell. 5:553–563. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zheng J, Li J, Xu L, Xie G, Wen Q, Luo J,
Li D, Huang D and Fan S: Phosphorylated Mnk1 and eIF4E are
associated with lymph node metastasis and poor prognosis of
nasopharyngeal carcinoma. PLoS One. 9:e892202014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
De Benedetti A and Harris AL: eIF4E
expression in tumors: Its possible role in progression of
malignancies. Int J Biochem Cell Biol. 31:59–72. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nathan CO, Franklin S, Abreo FW, Nassar R,
de Benedetti A, Williams J and Stucker FJ: Expression of eIF4E
during head and neck tumorigenesis: Possible role in angiogenesis.
Laryngoscope. 109:1253–1258. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sorrells DL Jr, Ghali GE, De Benedetti A,
Nathan CO and Li BD: Progressive amplification and overexpression
of the eukaryotic initiation factor 4E gene in different zones of
head and neck cancers. J Oral Maxillofac Surg. 57:294–299. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wu M, Liu Y, Di X, Kang H, Zeng H, Zhao Y,
Cai K, Pang T, Wang S, Yao Y, et al: EIF4E over-expresses and
enhances cell proliferation and cell cycle progression in
nasopharyngeal carcinoma. Med Oncol. 30:4002013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pawlik TM and Keyomarsi K: Role of cell
cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol
Biol Phys. 59:928–942. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Culjkovic B, Topisirovic I, Skrabanek L,
Ruiz-Gutierrez M and Borden KL: eIF4E is a central node of an RNA
regulon that governs cellular proliferation. J Cell Biol.
175:415–426. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Culjkovic-Kraljacic B, Baguet A, Volpon L,
Amri A and Borden KL: The oncogene eIF4E reprograms the nuclear
pore complex to promote mRNA export and oncogenic transformation.
Cell Rep. 2:207–215. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Goberdhan DCI and Boyd CAR: mTOR:
Dissecting regulation and mechanism of action to understand human
disease. Biochem Soc Trans. 37:213–216. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang W, Wen Q, Xu L, Xie G, Li J, Luo J,
Chu S, Shi L, Huang D, Li J, et al: Activation of Akt/mTOR pathway
is associated with poor prognosis of nasopharyngeal carcinoma. PLoS
One. 9:e1060982014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Albert JM, Kim KW, Cao C and Lu B:
Targeting the Akt/mammalian target of rapamycin pathway for
radiosensitization of breast cancer. Mol Cancer Ther. 5:1183–1189.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Brown JM: The hypoxic cell: A target for
selective cancer therapy - eighteenth Bruce F. Cain Memorial Award
lecture. Cancer Res. 59:5863–5870. 1999.PubMed/NCBI
|
|
37
|
Magagnin MG, van den Beucken T, Sergeant
K, Lambin P, Koritzinsky M, Devreese B and Wouters BG: The mTOR
target 4E-BP1 contributes to differential protein expression during
normoxia and hypoxia through changes in mRNA translation
efficiency. Proteomics. 8:1019–1028. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Braunstein S, Badura ML, Xi Q, Formenti SC
and Schneider RJ: Regulation of protein synthesis by ionizing
radiation. Mol Cell Biol. 29:5645–5656. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dubois L, Magagnin MG, Cleven AH, Weppler
SA, Grenacher B, Landuyt W, Lieuwes N, Lambin P, Gorr TA,
Koritzinsky M, et al: Inhibition of 4E-BP1 sensitizes U87
glioblastoma xenograft tumors to irradiation by decreasing hypoxia
tolerance. Int J Radiat Oncol Biol Phys. 73:1219–1227. 2009.
View Article : Google Scholar : PubMed/NCBI
|
